Skip to main content

Table 3 Best response to CXD101 in patients dosed at CXD101 doses of ≥16 mg twice daily

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Response Solid organ, all HR23B positive N = 11 Lymphoma HR23B Negative N = 7 Lymphoma HR23B Positive N = 15 Lymphoma HR23B score not available N = 1 Lymphoma total N = 23 All patients N = 34
NE 2 1 0 0 3 5
PD 5 2 7 1 8 13
SD 4 2 6 0 8 12
PR 0 2 1 0 3 3
CR 0 0 1 0 1 1
ORR 0 29% 13% 0% 17% 12%
  1. Responses shown according to RECIST v 1.1 for solid organ cancers and Cheson 2014 for lymphomas. HR23B status shown according to immunohistochemistry score on baseline tumour biopsy
  2. NE not evaluable, PD progressive disease, SD stable disease, PR partial response, CR complete response, ORR Overall response rate (PR + CR)